Risk of metachronous colorectal cancer after colectomy for first colon cancer in Lynch syndrome : multicenter retrospective study in Japan
© 2023. The Author(s) under exclusive licence to Japan Society of Clinical Oncology..
BACKGROUND: We evaluated the risk of metachronous colorectal cancer (mCRC) and explored the optimal extent of colectomy in patients with Lynch syndrome (LS) and first colon cancer (fCC) in Japan, where the extent of colectomy for colon cancer (CC) is shorter than that in Western countries.
METHODS: The clinicopathologic and survival data of patients with LS who developed CC were collected from a nationwide database and analyzed retrospectively. The cumulative incidence of mCRC after actual segmental colectomy was compared with that of mCRC when more extensive colectomy was assumed.
RESULTS: There were 142 eligible patients (65 female). The median age at fCC surgery was 46.5 (range: 14-80) years. The cumulative incidence of 5-, 10-, and 20-year mCRC rate was 13.4%, 20.8%, and 53.6%, respectively. The incidence was higher in the left-sided group (splenic flexure to rectosigmoid colon, n = 54) than in the right-sided group (cecum to transvers colon, n = 88) (66.3% vs. 45.3% in 20 years, P < 0.01). Assuming that all patients would have undergone hemicolectomy or total colectomy, the estimated mCRC risk was 41.5% and 9.4% (P < 0.01, vs. actual procedures), respectively. The 20-year overall survival rate of all the patients was 83.3% without difference by fCC sidedness (P = 0.38).
CONCLUSIONS: To reduce the incidence of mCRC, patients with genetically diagnosed LS and fCC, preferentially located in the left-sided colon, may need to undergo more extended colectomy than that usually performed in Japan. However, such extended colectomy should be counterbalanced with favorable overall survival and actual risk of mCRC development.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
International journal of clinical oncology - 28(2023), 12 vom: 15. Dez., Seite 1633-1640 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chikatani, Kenichi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Colorectal cancer |
|---|
| Anmerkungen: |
Date Completed 21.12.2023 Date Revised 21.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10147-023-02412-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362487030 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362487030 | ||
| 003 | DE-627 | ||
| 005 | 20231227135312.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10147-023-02412-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1234.xml |
| 035 | |a (DE-627)NLM362487030 | ||
| 035 | |a (NLM)37752370 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chikatani, Kenichi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Risk of metachronous colorectal cancer after colectomy for first colon cancer in Lynch syndrome |b multicenter retrospective study in Japan |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.12.2023 | ||
| 500 | |a Date Revised 21.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s) under exclusive licence to Japan Society of Clinical Oncology. | ||
| 520 | |a BACKGROUND: We evaluated the risk of metachronous colorectal cancer (mCRC) and explored the optimal extent of colectomy in patients with Lynch syndrome (LS) and first colon cancer (fCC) in Japan, where the extent of colectomy for colon cancer (CC) is shorter than that in Western countries | ||
| 520 | |a METHODS: The clinicopathologic and survival data of patients with LS who developed CC were collected from a nationwide database and analyzed retrospectively. The cumulative incidence of mCRC after actual segmental colectomy was compared with that of mCRC when more extensive colectomy was assumed | ||
| 520 | |a RESULTS: There were 142 eligible patients (65 female). The median age at fCC surgery was 46.5 (range: 14-80) years. The cumulative incidence of 5-, 10-, and 20-year mCRC rate was 13.4%, 20.8%, and 53.6%, respectively. The incidence was higher in the left-sided group (splenic flexure to rectosigmoid colon, n = 54) than in the right-sided group (cecum to transvers colon, n = 88) (66.3% vs. 45.3% in 20 years, P < 0.01). Assuming that all patients would have undergone hemicolectomy or total colectomy, the estimated mCRC risk was 41.5% and 9.4% (P < 0.01, vs. actual procedures), respectively. The 20-year overall survival rate of all the patients was 83.3% without difference by fCC sidedness (P = 0.38) | ||
| 520 | |a CONCLUSIONS: To reduce the incidence of mCRC, patients with genetically diagnosed LS and fCC, preferentially located in the left-sided colon, may need to undergo more extended colectomy than that usually performed in Japan. However, such extended colectomy should be counterbalanced with favorable overall survival and actual risk of mCRC development | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Colorectal cancer | |
| 650 | 4 | |a Lynch syndrome | |
| 650 | 4 | |a Metachronous colorectal cancer | |
| 700 | 1 | |a Ishida, Hideyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Mori, Yoshiko |e verfasserin |4 aut | |
| 700 | 1 | |a Nakajima, Takeshi |e verfasserin |4 aut | |
| 700 | 1 | |a Ueki, Arisa |e verfasserin |4 aut | |
| 700 | 1 | |a Akagi, Kiwamu |e verfasserin |4 aut | |
| 700 | 1 | |a Takao, Akinari |e verfasserin |4 aut | |
| 700 | 1 | |a Yamada, Masayoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Taniguchi, Fumitaka |e verfasserin |4 aut | |
| 700 | 1 | |a Komori, Koji |e verfasserin |4 aut | |
| 700 | 1 | |a Sasaki, Kazuhito |e verfasserin |4 aut | |
| 700 | 1 | |a Sudo, Tomoya |e verfasserin |4 aut | |
| 700 | 1 | |a Miyakura, Yasuyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Chino, Akiko |e verfasserin |4 aut | |
| 700 | 1 | |a Yamaguchi, Tatsuro |e verfasserin |4 aut | |
| 700 | 1 | |a Tanakaya, Kohji |e verfasserin |4 aut | |
| 700 | 1 | |a Tomita, Naohiro |e verfasserin |4 aut | |
| 700 | 1 | |a Ajioka, Yoichi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of clinical oncology |d 1997 |g 28(2023), 12 vom: 15. Dez., Seite 1633-1640 |w (DE-627)NLM095566163 |x 1437-7772 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2023 |g number:12 |g day:15 |g month:12 |g pages:1633-1640 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10147-023-02412-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2023 |e 12 |b 15 |c 12 |h 1633-1640 | ||